Rolf Marschalek mainly focuses on Genetics, Leukemia, Chromosomal translocation, Gene rearrangement and Immunology. His Genetics study frequently links to related topics such as Cell biology. His Leukemia research incorporates themes from Oncology, Myeloid leukemia, Allele, Myeloid-Lymphoid Leukemia Protein and Oncogene Proteins.
His studies in Chromosomal translocation integrate themes in fields like Fusion gene and Acute lymphocytic leukemia. His Gene rearrangement study also includes
His scientific interests lie mostly in Genetics, Chromosomal translocation, Molecular biology, Gene and Leukemia. His study in Breakpoint, Fusion gene, Exon, breakpoint cluster region and Intron falls under the purview of Genetics. In his study, Oncology is strongly linked to Minimal residual disease, which falls under the umbrella field of Fusion gene.
Gene rearrangement is closely connected to Acute lymphocytic leukemia in his research, which is encompassed under the umbrella topic of Chromosomal translocation. His Molecular biology research is multidisciplinary, incorporating perspectives in Transcription, Fusion transcript and Gene expression profiling. His work carried out in the field of Leukemia brings together such families of science as Myeloid-Lymphoid Leukemia Protein and Cancer research, Myeloid leukemia.
Rolf Marschalek spends much of his time researching Cancer research, Leukemia, KMT2A, Molecular biology and Genetics. His research integrates issues of Downregulation and upregulation and Real-time polymerase chain reaction in his study of Cancer research. Rolf Marschalek combines subjects such as Myeloid-Lymphoid Leukemia Protein, Haematopoiesis, breakpoint cluster region and Chromosomal translocation with his study of Leukemia.
His research in Chromosomal translocation focuses on subjects like Acute leukemia, which are connected to Fusion gene and Gene rearrangement. He works mostly in the field of KMT2A, limiting it down to topics relating to Minimal residual disease and, in certain cases, Oncology, Fusion transcript and Breakpoint. His Molecular biology study incorporates themes from HEK 293 cells and Messenger RNA.
The scientist’s investigation covers issues in Myeloid-Lymphoid Leukemia Protein, Leukemia, Molecular biology, Cancer research and Genetics. His Myeloid-Lymphoid Leukemia Protein research is multidisciplinary, incorporating elements of Cancer, Pathogenesis, Minimal residual disease, Disease and Leukemogenic. His Leukemia study combines topics in areas such as Cytotoxicity and Chromosomal translocation.
His study in Molecular biology is interdisciplinary in nature, drawing from both Transcription factor II A, Enzyme activator, Messenger RNA and Transcription. His study in the field of Myeloid leukemia also crosses realms of Cancer immunotherapy. His research on Genetics often connects related topics like Cell biology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The MLL recombinome of acute leukemias in 2013
C. Meyer;J. Hofmann;T. Burmeister;D. Gröger.
New insights to the MLL recombinome of acute leukemias
C. Meyer;E. Kowarz;J. Hofmann;A. Renneville.
The MLL recombinome of acute leukemias in 2017
C Meyer;T Burmeister;D Gröger;G Tsaur.
The MLL recombinome of acute leukemias.
C. Meyer;B. Schneider;S. Jakob;S. Strehl.
Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
U M Schrell;M G Rittig;M Anders;U H Koch.
Journal of Neurosurgery (1997)
Diagnostic tool for the identification of MLL rearrangements including unknown partner genes
Claus Meyer;Bjoern Schneider;Martin Reichel;Sieglinde Angermueller.
Proceedings of the National Academy of Sciences of the United States of America (2005)
Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma
Huriye Cin;Claus Meyer;Ricarda Herr;Wibke G. Janzarik.
Acta Neuropathologica (2011)
Mechanisms of leukemogenesis by MLL fusion proteins.
British Journal of Haematology (2011)
Optimized Sleeping Beauty transposons rapidly generate stable transgenic cell lines.
Eric Kowarz;Denise Löscher;Rolf Marschalek.
Biotechnology Journal (2015)
Exon/intron structure of the human ALL‐1 (MLL) gene involved in translocations to chromosomal region 11q23 and acute leukaemias
I. Nilson;K. LöCHNER;G. Siegler;J. Greil.
British Journal of Haematology (1996)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: